Insulin Aspart 30 biosimilar (Gan & Lee Pharma)

门冬胰岛素30生物类似药（甘李药业）

Report date: 2026/05/27 10:23:25

Base Information

Drug NameInsulin Aspart 30 biosimilar (Gan & Lee Pharma)
Drug Alias NameAspart 30门冬胰岛素30注射液锐秀霖30Rui Xiu Lin 30Rapilin®30 +[6] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormoneBiologics > Biosimilar
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsDiabetes Mellitus
Approved Indications in ChinaDiabetes Mellitus
Original Approved Country/TerritoryMainland China
Original Approved Date2020/12/02
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGan & Lee Pharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesGan & Lee Pharmaceuticals
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A